Skip to content
DataLookout
Menu

NCT07761910

Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 6 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date pushed from Sep 2026 to Jan 2027
  2. Notable Primary completion pushed from Dec 2026 to Jul 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Study completion pushed from Mar 2027 to Oct 2027
    • Interventions: 18F-Flurpiridaz (Drug), Coronary CT Angiography (CCTA) (Device), PET/CT 18F-Flurpiridaz Rest/Stress Test (Diagnostic Test) to 18F-Flurpiridaz (Drug), Coronary CT Angiography (CCTA) (Device), PET/CT 18F-Flurpiridaz Rest/Stress Test (Diagnostic Test)
    • Secondary endpoints: details revised at 4 of 4 entries
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change of MBF (myocardial blood flow)
Timeframe: Pre-radiotherapy and 3 months post-radiotherapy

Secondary (4)

Changes in myocardial blood flow to the cardiac base
Changes in myocardial blood flow to the left ventricle
Changes in myocardial blood flow to right coronary artery
Changes in myocardial blood flow to left circumflex artery

Arms and interventions

PET/CT 18F-Flurpiridaz Rest/Stress TestExperimental

A two-phase, rest and regadenoson stress evaluated by 18F-Flurpiridaz PET/CT before and 3 months after SOC radiation treatment.

Diagnostic tests: PET/CT 18F-Flurpiridaz Rest/Stress Test

Devices: Coronary CT Angiography (CCTA)

Drugs: 18F-Flurpiridaz

Sites

1 site in 1 country

  • Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis, Indiana, United States